Rheumatoid Arthritis

Analysis of self-reported wellness and health may provide insight into an overall subjective picture of wellbeing and health status. Mood, sleep quality, and sleep quantity were shown to impact these scores.

Early diagnosis and prompt effective management are important for the best outcomes in rheumatoid arthritis. Test your knowledge of how to achieve this with this quiz.

While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.

While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.

An increased frequency of serious infections and antimicrobial prescriptions was seen in patients with rheumatoid arthritis currently being treated with a TNFi.

Treatment for rheumatoid arthritis has been associated with the development and worsening of some lung conditions. Test your knowledge with this quiz.

Patients with rheumatoid arthritis often have lung conditions. How much do you know about the risks of lung disease associated with rheumatoid arthritis? Test your knowledge with this quiz.

Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis.

Test your knowledge of the treatment and management of rheumatoid arthritis with our latest RA quizzes.

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

Selective Janus kinase (JAK) inhibitor, upadacitinib, is now intended for adults with moderate-to-severe rheumatoid arthritis (RA) who have had inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker.

Rheumatoid arthritis often requires long-term treatment with disease-modifying antirheumatic drugs (DMARDs), but tapering and even cessation of DMARDs can be considered for patients in remission. Test your knowledge of use of DMARDs in patients in remission with this quiz.

Andrew Concoff, MD, explores the benefits of a gel that significantly improves clinical outcomes for patients with rheumatoid arthritis and decreases the need for concomitant medications.

Janus kinase (JAK) inhibitors are the newest class of drugs used to treat rheumatoid arthritis. How much do you know about these drugs? Test your knowledge with this quiz.

Rheumatoid arthritis is a complex condition. How much do you know about RA treatment?

Jeffrey Curtis, MD, MS, MPH, discusses malignancies in older patients with rheumatoid arthritis and cardiovascular risks being treated with either tofacitinib or tumor necrosis factor (TNF) inhibitors.

While statin initiation was associated with reducing the risk of cardiovascular disease, it may increase in the risk of developing diabetes in patients with rheumatoid arthritis.

An interview on new findings suggesting baseline heart failure may be an indicator of increased mortality risk in patients treating arthritis with the DMARD.

Patients are increasingly encouraged to take an active role in the management of their chronic conditions. How much do you know about self-management in rheumatoid arthritis?

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

This study shows that many patients with rheumatoid arthritis can use a dose lower than 1000mg and still see results.

Nathan den Broeder, MSs, shares the findings of his study at the ACR 2021 Convergence.

A new ACR 2021 study suggests patients on the biologic may be less likely to discontinue treatment than those receiving other drug classes.

Vibeke Strand, MD, explores her ACR presentation, “Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib.”

Joshua Solomon, MD, discusses his upcoming ACR presentation entitled, “A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.”